我们通过实时检索，整理了近期围绕 Relmada Therapeutics, Inc.（RLMD）人工智能布局的公开报道与信息。以下内容均摘自可核实的来源链接，供读者交叉验证。
Positive factors (green) increase the probability of beating the market, while negative factors (red) reduce it. ... Alpha Signals show the individual signals used by Danelfin's AI to calculate a stock's probability of beating the market over the next 3 months…
来源：Relmada Therapeutics Inc (RLMD) Stock AI Rating &
Perplexity is a free AI-powered answer engine that provides accurate, trusted, and real-time answers to any question.
来源：Relmada Therapeutics, Inc. Stock Price
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Kuehn Law Encourages Investors of Relmada Therapeutics, Inc.
来源：Relmada Therapeutics, Inc. Stock — RLMD Overview —
客观分析
Relmada Therapeutics是一家临床阶段生物技术公司，专注于中枢神经系统疾病及其他疾病的疗法开发。报道援引Danelfin的AI评级工具，称其正面信号提升了股票跑赢市场的概率，但未披露具体信号内容；同时提及Perplexity等AI工具提供股价查询服务。整体信息以AI投资分析工具对个股的评价为主，缺乏公司研发管线、临床数据等实质进展。